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(range 31-318). The overall probability of developing 
CMVR was 1.07+0.26%. CMVR was more common in 
the patients who had chronic GVHD ((2.08% (p=O.O6)) 
and even higher in patients with extensive chronic 
GVHD ((2.31% (p=O.O5)). In multivariate analysis the 
risk factors for CMVR were having a CMV seronegative 
donor to a CMV seropositive patients, use of peripheral 
blood stem cells, year of SCT later than 1995, and T-cell 
depletion. 
In conclusion, the study supports that CMVR has 
become more common after allogeneic SCT and that 
transferred donor T-cell immunity is an important 
protective factor against CMVR. 
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Vancomycin-resistant Enterococcus faecium (VREF) 
continues to be a problem pathogen, particularly for 
immuncompromised patients such as bone marrow 
transplant patients. Rates of colonization are higher 
than infection, but VREF infections in bone marrow 
transplant patients are associated with high mortality 
despite new options for therapy. Our bone marrow 
transplant units experience a VREF colonization rate of 
12 per cent, or 11.4 cases per 1,000 patient days.This was 
associated with the occurrence of several serious clinical 
infections. Interventions included institution of routine 
surveillance VREF cultures on admission to the unit 
and weekly thereafter to identify VREF cases earlier 
for Contact Precautions, availability of instant antisepsis, 
environmental cultures as epidemiologically indicated 
and re-inservicing of housekeeping staff regarding 
appropriate daily cleaning on the unit, use of a 
germicide with a more acceptable smell for patient 
acceptance, inservicing of unit staff including results of 
pulsed-field gel electrophoresis typing of VREF patient 
and environmental isolates, and rotation of antibiotic 
regimens for empiric therapy of febrile neutropenia 
(piperacillim tazobactam and cefipime rotated every 
three months). Results in two years of follow-up after 
the interventions included a decrease in VREF colon- 
ization prevalence to 6 per cent, or 2 to 5 cases per 
1,000 patient days; clinical VREF infections were 
rare. The routine use of surveillance cultures, enhanced 
antisepsis, improved environmental cleaning, staff 
education regarding VREF strain transmission, and 
antibiotic utilization patterns may be useful in control- 
ling rates of VREF in high-risk immunocompromised 
patients. 
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Invasive fungal infections are a leading cause of 
morbidity and mortality in allogeneic bone marrow 
transplant (BMT) patients both early and late after 
transplant. In this multicenter trial, allogeneic BMT 
patients were randomized to receive long-term anti- 
fungal prophylaxis with either itraconazole (ITRA) (200 
rng IV ql2hrs for 2 days followed by 200 mg IV q24hrs 
or 200 mg oral solution ql2hrs) or fluconazole (FLU) 
(400 mg IV or orally q24hrs.) from day 1 until day 100 
after BMT. Each study drug was given IV for the first 
14 days followed by oral therapy. Patients unable to 
take oral therapy returned to IV study drug. 71 patients 
received ITRA; 67 patients received FLU. Proven 
invasive fungal infections occurred in 6/71 (9%) ITRA 
patients and 17/67 (25%) FLU patients within 180 
days after BMT (P=O.Ol). Proven superficial fungal 
infections occurred in 3/71(4%) ITRA patients and 2/67 
(3%) FLU patients. In a multivariate regression 
analysis using factors known to affect the risk of invasive 
fungal infection after BMT, prophylaxis with ITRA was 
still associated with a lower risk for invasive fungal 
infection (p=O.O2) caused by either yeasts or molds. 
Death from fungal infection occurred in 6/71 (9%) 
ITRA patients and 12167 (18%) FLU patients (p=O.13). 
Both ITRA and FLU were generally well-tolerated. 
Gastrointestinal adverse events (nausea, vomiting, 
diarrhea, abdominal pain) were more frequent in ITRA 
patients (17/71 or 24% vs. 6167 or 9%, p=O.O2). There 
was no appreciable hepatotoxicity with either ITRA or 
FLU. These results suggest that IV/oral ITRA may 
be more effective than IV/oral FLU for long-term 
prophylaxis of early and late invasive fungal infections 
after allogeneic BMT. 
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In the fall of 2001 during a 3-week interval 3 heart 
transplant patients at our hospital were diagnosed with 
nocardia infections. Two patients received their trans- 
plants in 2001 and the third in 1997. All were male 
between 60 and 70 years old. 
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Patient A received his transplant in July 2001. Cardiac 
biopsies showed no rejection on a stable immuno- 
suppressive regimen of mycophenolate, tacrolimus and 
prednisone. Renal status was stable with a creatinine 
of 1.4mg/dl and CMV prophylaxis with ganciclovir 
and valganciclovir was used. PCP prophylaxis with 
pentamidine was given. In mid October a BAL culture 
grew Aspergillus and Nocardia. Treatment was begun 
with tmp/smz, imipenem, and caspofungin plus lipid 
formulation amphotericin B. Ventilatory support and 
chest tube drainage were needed, and CT imaging showed 
cranial involvement. The patient died in December. 
Patient B received his heart transplant in 1997. 
Surveillance heart biopsies showed no evidence of 
rejection and renal function was stable with a creatinine 
around 2mg/dl. PCP prophylaxis with tmp/smz was given 
for two years until July 1999. The patient developed 
persistent pleural effusions that reoccurred in spite of 
repeated drainage. Specimens from surgical decortication 
and evacuation of the effusions grew Nocardia that was 
treated with IV tmp/smz for one month. An MRI did not 
show any intracranial lesions. Outpatient treatment with 
oral tmp/smz was continued. 
The third patient received his transplant in February 
2001. Myocardial biopsies confirmed grade I and grade 
III rejection 2 months and 7 months post transplantation 
respectively. In the second instance a short-term increase 
in immunosuppression was given. The patient also 
received lamivudine and ganciclovir because the donor 
was hepatitis B core antibody positive and had positive 
CMV serology. Prophylaxis with tmp/smz three times 
weekly was begun in March. Renal function was stable. 
Subsequent to respiratory complaints a CT of the chest 
was obtained in October and showed a significant pul- 
monary lesion. Bronchoscopy specimens grew Nocardia 
and Aspergillus. Imaging of the head did not reveal any 
cranial involvement. IV treatment with caspofungin, 
imipenem and cefotaxime continued through the middle 
of December with improvement of the pulmonary 
lesions on repeat CT. The patient was discharged on 
outpatient oral therapy with tmp/smz and itraconazole. 
This uncanny cluster of nocardia infections in heart 
transplant patients exhibits the importance of consider- 
ing Nocardia as opportunistic pathogens in transplant 
patients even if tmp/smz prophylaxis has been given. 
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Introduction: Cytomegalovirus reactivation is common 
and carries serious morbidity and high mortality in 
patients undergoing allogeneic marrow transplantation, 
especially in recipients of marrow grafts from CMV- 
seropositive donors. The impact of early viral reactivation 
on response to antiviral treatment is uncertain. 
Methods: Seven recipients of two and greater than two 
HLA-antigen mismatched, related marrow transplant- 
ation during 1999-2000 were evaluated prospectively for 
CMV viremia by real-time PCR technique (Speciality 
Laboratories, Santa Monica, CA) performed on post- 
transplantation day + 1, and than weekly. All values are 
given in median+standard deviation. 
Results: Five had refractory or recurrent acute myelo- 
genous leukemia (AML), and two with acute lympho- 
cytic leukemia (ALL). Four received 3 HLA-antigen 
mismatched marrow grafts from a related donor. Three 
had evidence of CMV in the peripheral blood on 12+5 
days (age 17+11 years), whereas four (age 26+24 years) 
had evidence of reactivation on 30-t 4 days following 
BMT. In the sub-group with early reactivation (day 
12+5), median CMV viral load was 258+91 copies/ml, 
and 1291+4220 copies/ml in the remaining four (P~0.5). 
Four patients had clinical and virological failure to initial 
therapy with ganciclovir (5 mg/kg every 12 hours). 
Among these, two (2/3; 66.7%) patients had evidence of 
early CMV reactivation and the other two (2/4; 50%) 
had evidence of reactivation around post transplant day 
+30 (P>O.5). 
Conclusions: Cytomegalovirus reactivation during the 
first two weeks of transplantation was associated with 
low-grade viremia. We did not observed a significant 
association with early CMV reactivation and failure to 
initial ganciclovir therapy in patients following high-risk 
allogeneic marrow transplantation. 
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Background and objective:. The present study was 
undertaken to evaluate the therapeutic effects of 
pancreatic beta-cells in diabetic animals immunized by 
Escherichi coli vaccine. 
Study design/ materials and methods: Ten days after 
streptozocin injection (60 mg/ kg), diabetic rats received 
intraperitoneal injection of pancreatic beta-cells 
(5.7~10~ cells/rat). Twelve days later both the diabetic 
and healthy animals were immunized by oral route with 
enteroinvasive E. coli (0136 serotype) acetone-killed 
vaccine. Twenty-one days after beta-cells transplantation 
lamina propria and Peyer’s patches lymphoid T cells 
were obtained from the intestine. 
